St. Jude Medical Gets FDA Letter On Atrial Fibrillation Plant

April 21, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WSJ -- St. Jude Medical Inc. (STJ) received on Tuesday a Food and Drug Administration warning letter regarding issues at a Minnesota facility where the company makes products to fix a common heart-rhythm disorder called atrial fibrillation.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

Food and Drug Administration (FDA)